Enhancement of proteasome function by PA28α overexpression protects against oxidative stress

The principal function of the proteasome is targeted degradation of intracellular proteins. Proteasome dysfunction has been observed in experimental cardiomyopathies and implicated in human congestive heart failure. Measures to enhance proteasome proteolytic function are currently lacking but would be beneficial in testing the pathogenic role of proteasome dysfunction and could have significant therapeutic potential. The association of proteasome activator 28 (PA28) with the 20S proteasome may play a role in antigen processing. It is unclear, however, whether the PA28 plays any important role outside of antigen presentation, although up‐regulation of PA28 has been observed in certain types of cardiomyopathy. Here, we show that PA28α overexpression (PA28αOE) stabilized PA28β, increased 11S proteasomes, and enhanced the degradation of a previously validated proteasome surrogate substrate (GFPu) in cultured neonatal rat cardiomyocytes. PA28αOE significantly attenuated H2O2‐induced increases in the protein carbonyls and markedly suppressed apoptosis in cultured cardiomyocytes under basal conditions or when stressed by H2O2. We conclude that PA28αOE is sufficient to up‐regulate 11S proteasomes, enhance proteasome‐mediated removal of misfolded and oxidized proteins, and protect against oxidative stress in cardiomyocytes, providing a highly sought means to increase proteasomal degradation of abnormal cellular proteins.—Li, J., Powell, S. R., Wang, X. Enhancement of proteasome function by PA28α overexpression protects against oxidative stress. FASEB J. 25, 883–893 (2011). www.fasebj.org

[1]  J. Li,et al.  Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. , 2010, Cardiovascular research.

[2]  Q. Dou,et al.  Physiological levels of ATP negatively regulate proteasome function , 2010, Cell Research.

[3]  A. Gomes,et al.  Myocardial Ischemic Preconditioning Preserves Postischemic Function of the 26S Proteasome Through Diminished Oxidative Damage to 19S Regulatory Particle Subunits , 2010, Circulation research.

[4]  F. Pagani,et al.  Ubiquitin Proteasome Dysfunction in Human Hypertrophic and Dilated Cardiomyopathies , 2010, Circulation.

[5]  Silke Meiners,et al.  Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. , 2010, Cardiovascular research.

[6]  Xuejun Wang,et al.  The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. , 2010, Cardiovascular research.

[7]  Wei Huang,et al.  The COP9 signalosome negatively regulates proteasome proteolytic function and is essential to transcription. , 2009, The international journal of biochemistry & cell biology.

[8]  P. Ping,et al.  Contrasting Proteome Biology and Functional Heterogeneity of the 20 S Proteasome Complexes in Mammalian Tissues*S , 2009, Molecular & Cellular Proteomics.

[9]  J. Taylor,et al.  Selective Accumulation of Aggregation-Prone Proteasome Substrates in Response to Proteotoxic Stress , 2009, Molecular and Cellular Biology.

[10]  I. Hisatome,et al.  Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. , 2008, Journal of molecular biology.

[11]  P. Ping,et al.  Revealing the Dynamics of the 20 S Proteasome Phosphoproteome , 2008, Molecular & Cellular Proteomics.

[12]  Tommer Ravid,et al.  Diversity of degradation signals in the ubiquitin–proteasome system , 2008, Nature Reviews Molecular Cell Biology.

[13]  Xuejun Wang,et al.  Protein quality control and degradation in cardiomyocytes. , 2008, Journal of molecular and cellular cardiology.

[14]  Janet L. Johnstone,et al.  Intracellular Protein Aggregation Is a Proximal Trigger of Cardiomyocyte Autophagy , 2008, Circulation.

[15]  P. Ping,et al.  Understanding proteasome assembly and regulation: importance to cardiovascular medicine. , 2008, Trends in cardiovascular medicine.

[16]  N. Maulik,et al.  Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. , 2008, Journal of molecular and cellular cardiology.

[17]  Peipei Ping,et al.  Mammalian Proteasome Subpopulations with Distinct Molecular Compositions and Proteolytic Activities* , 2007, Molecular & Cellular Proteomics.

[18]  L. Lerman,et al.  Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis , 2007, Circulation research.

[19]  James M. Roberts,et al.  Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. , 2007, Molecular cell.

[20]  B. O’Malley,et al.  Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. , 2007, Molecular cell.

[21]  C. Patterson,et al.  The Bitter End: The Ubiquitin-Proteasome System and Cardiac Dysfunction , 2007, Circulation.

[22]  Xuejun Wang,et al.  Heart failure and protein quality control. , 2006, Circulation research.

[23]  Peipei Ping,et al.  Regulation of Murine Cardiac 20S Proteasomes: Role of Associating Partners , 2006, Circulation research.

[24]  P. Ping,et al.  Mapping the Murine Cardiac 26S Proteasome Complexes , 2006, Circulation research.

[25]  Jinbao Liu,et al.  Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. , 2006, Journal of molecular and cellular cardiology.

[26]  S. Powell.  The ubiquitin-proteasome system in cardiac physiology and pathology. , 2006, American journal of physiology. Heart and circulatory physiology.

[27]  Jinbao Liu,et al.  Impairment of the ubiquitin‐proteasome system in desminopathy mouse hearts , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Malovannaya,et al.  The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitin- and ATP-Independent Manner by the REGγ Proteasome , 2006, Cell.

[29]  Jinbao Liu,et al.  Intrasarcoplasmic Amyloidosis Impairs Proteolytic Function of Proteasomes in Cardiomyocytes by Compromising Substrate Uptake , 2005, Circulation research.

[30]  D. Ferrington,et al.  Altered proteasome structure, function, and oxidation in aged muscle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  K. Lindenberg,et al.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.

[32]  Jennifer E. Whittier,et al.  Hsp90 Enhances Degradation of Oxidized Calmodulin by the 20 S Proteasome* , 2004, Journal of Biological Chemistry.

[33]  Jinbao Liu,et al.  In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. , 2004, American journal of physiology. Heart and circulatory physiology.

[34]  J. Saffitz,et al.  Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Lance F. Barton,et al.  Immune Defects in 28-kDa Proteasome Activator γ-Deficient Mice1 , 2004, The Journal of Immunology.

[36]  Keiji Tanaka,et al.  The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome , 2003, The EMBO journal.

[37]  Michael J Dunn,et al.  Hyperubiquitination of proteins in dilated cardiomyopathy , 2003, Proteomics.

[38]  Keiji Tanaka,et al.  Two Distinct Pathways Mediated by PA28 and hsp90 in Major Histocompatibility Complex Class I Antigen Processing , 2002, The Journal of experimental medicine.

[39]  A. Goldberg,et al.  Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes , 2002, The EMBO journal.

[40]  Tomoki Chiba,et al.  Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β , 2001 .

[41]  J. Robbins,et al.  The Tumor Suppressor Gene PTEN Can Regulate Cardiac Hypertrophy and Survival* , 2001, The Journal of Biological Chemistry.

[42]  M. Orłowski,et al.  Heat shock protein-90 and the catalytic activities of the 20 S proteasome (multicatalytic proteinase complex). , 2001, Archives of biochemistry and biophysics.

[43]  C. Hill,et al.  Structural basis for the activation of 20S proteasomes by 11S regulators , 2000, Nature.

[44]  P. Kloetzel,et al.  Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28. , 2000, European journal of biochemistry.

[45]  R. G. Kulka,et al.  Degradation Signals Recognized by the Ubc6p-Ubc7p Ubiquitin-Conjugating Enzyme Pair , 2000, Molecular and Cellular Biology.

[46]  Y. Murakami,et al.  Hybrid Proteasomes , 2000, The Journal of Biological Chemistry.

[47]  H. Kawasaki,et al.  A Critical Role for the Proteasome Activator PA28 in the Hsp90-dependent Protein Refolding* , 2000, The Journal of Biological Chemistry.

[48]  M. Kasahara,et al.  Growth Retardation in Mice Lacking the Proteasome Activator PA28γ* , 1999, The Journal of Biological Chemistry.

[49]  A. Vitiello,et al.  Impaired immunoproteasome assembly and immune responses in PA28-/- mice. , 1999, Science.

[50]  K. Standing,et al.  Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero-oligomers are heptamers. , 1999, Biochemistry.

[51]  C. Hill,et al.  Characterization of Recombinant REGα, REGβ, and REGγ Proteasome Activators* , 1997, The Journal of Biological Chemistry.

[52]  C. Slaughter,et al.  A Model for the Quaternary Structure of the Proteasome Activator PA28* , 1996, The Journal of Biological Chemistry.

[53]  Hans-Georg Rammensee,et al.  A role for the proteasome regulator PA28α in antigen presentation , 1996, Nature.

[54]  Xiaosong Liu,et al.  The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. , 2009, Cellular immunology.

[55]  K. Davies,et al.  Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. , 2007, Journal of molecular and cellular cardiology.

[56]  A. Goldberg,et al.  Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation. , 2005, Methods in enzymology.

[57]  D. Ferrington,et al.  Altered proteasome function and subunit composition in aged muscle. , 2004, Archives of biochemistry and biophysics.

[58]  Lance F. Barton,et al.  Immune defects in 28-kDa proteasome activator gamma-deficient mice. , 2004, Journal of immunology.

[59]  M. Kasahara,et al.  Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. , 2001, The EMBO journal.

[60]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[61]  Y. Murakami,et al.  Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. , 2000, The Journal of biological chemistry.

[62]  P. Kloetzel,et al.  The Role of the Proteasome System and the Proteasome Activator PA28 Complex in the Cellular Immune Response , 1999, Biological chemistry.

[63]  C. Hill,et al.  Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. , 1997, The Journal of biological chemistry.

[64]  P. Kloetzel,et al.  A role for the proteasome regulator PA28alpha in antigen presentation. , 1996, Nature.

[65]  M. Willis,et al.  The Ubiquitin–proteasome System in Cardiac Dysfunction , 2022 .

[66]  J. Li,et al.  The FASEB Journal express article 10.1096/fj.05-3973fje. Published online September 27, 2005. , 2022 .